AmoyDx

AmoyDx (厦门艾德生物医药科技股份有限公司) was founded in 2008 by Professor Zheng Limou, a nationally recognized expert, focusing on molecular diagnostics in precision oncology. The company holds national enterprise technology center status and has proprietary technologies including ADx-ARMS®, Super-ARMS®, ddCapture®, and ADx-HANDLE®, with patents in China, the US, EU, and Japan. Products cover major cancer types; some products are approved in Japan and South Korea. AmoyDx is a strategic partner to AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Eisai, Hengrui, and BeiGene for oncology drug development. GMP facilities hold NMPA and EU ISO13485 certifications. Tens of millions of cancer patients benefit annually.